Phase 2 fail sends OcuTerra's eye drop dreams down the drain
OcuTerra to Present at 42nd Annual J.P. Morgan Healthcare Conference
OcuTerra Announces Last Patient Completes Final Visit in Nesvategrast
OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced the appointment of Bill Steinkrauss as Chief Financial Officer. Mr. Steinkrauss brings to OcuTerra over 15 years of financial and executive leadership experience and will lead financial strategy and operations as the company continues to advance its lead asset, OTT166, for the treatment of diabetic retinopathy.
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced the publication of a paper titled “The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study” in Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina). The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced the first patient was dosed in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy with minimal vision loss. OTT166 is a novel small molecule selective integrin inhibitor that is designed with purpose engineering to have the required physiochemical characteristics to be able to reach the retina from eye drop application.
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced the appointment of eye care industry veteran Majid Anderesi, MD, as Vice President of Clinical and Medical Affairs.
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch and wait” does not prevent or control the progression of disease, today announced the appointment of Barbara Ryan to its Board of Directors. In conjunction with this appointment, Robert Dempsey will step down as a Board member.